PERFECTING THE SCIENCE OF GENE DELIVERY
DEAD

Serial Number

78755195

Owner

Lentigen Corporation

Attorney

Eric S. Marzluf

Filing Date

Nov 16, 2005

Add to watchlist:

No watchlists yet
View on USPTO

PERFECTING THE SCIENCE OF GENE DELIVERY Trademark

Serial Number: 78755195

PERFECTING THE SCIENCE OF GENE DELIVERY is a trademark filed by Lentigen Corporation on November 16, 2005. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Lentigen Corporation (15 trademarks)

1450 South Rolling Road
Baltimore, MD 21227

Entity Type: 03

Trademark Details

Filing Date

November 16, 2005

Registration Date

Not Registered

Published for Opposition

May 2, 2006

Goods & Services

Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Drug delivery agents consisting compounds that facilitate delivery of a wide range of pharmaceuticals; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Injectable pharmaceuticals for treatment of anaphylactic reactions; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of central nervous system disorders, cardiovascular, dermatological, diabetic, infectious, respiratory, and hormonal disease; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations namely, anticoagulants; Pharmaceutical preparations namely,antidepressants; Pharmaceutical preparations namely,appetite suppressants; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals, namely, anti-infectives

Assays and reagents for use in genetic research; Biochemicals namely, polypeptides for in vitro research use; Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; Cells for scientific, laboratory or medical research

Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research and development; Pharmaceutical research services; Research and development of vaccines and medicines; Research on the subject of pharmaceuticals; Scientific research; Scientific research and development; Scientific research in the field of genetics and genetic engineering

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Mar 2, 2009 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 2, 2009 ABN6
SOU EXTENSION 4 GRANTED
Aug 6, 2008 EX4G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 5, 2008 AITU
SOU EXTENSION 4 FILED
Jul 23, 2008 EXT4
SOU TEAS EXTENSION RECEIVED
Jul 23, 2008 EEXT
SOU EXTENSION 3 GRANTED
Feb 12, 2008 EX3G
SOU EXTENSION 3 FILED
Jan 25, 2008 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 25, 2008 EEXT
SOU EXTENSION 2 GRANTED
Sep 14, 2007 EX2G
SOU EXTENSION 2 FILED
Jul 24, 2007 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 24, 2007 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 17, 2007 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 17, 2007 REAP
SOU EXTENSION 1 GRANTED
Jan 16, 2007 EX1G
SOU EXTENSION 1 FILED
Jan 16, 2007 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 16, 2007 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 12, 2007 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 12, 2007 REAP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 12, 2007 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 12, 2007 REAP
NOA MAILED - SOU REQUIRED FROM APPLICANT
Jul 25, 2006 NOAM
PUBLISHED FOR OPPOSITION
May 2, 2006 PUBO
NOTICE OF PUBLICATION
Apr 12, 2006 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 13, 2006 PREV
ASSIGNED TO LIE
Mar 3, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 27, 2006 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 17, 2006 XAEC
EXAMINERS AMENDMENT E-MAILED
Feb 17, 2006 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 17, 2006 CNEA
ASSIGNED TO EXAMINER
Feb 7, 2006 DOCK
NEW APPLICATION ENTERED
Nov 22, 2005 NWAP